Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $252.4 million.

  • Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity rose 16575.71% to $252.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $795.6 million, marking a year-over-year increase of 7481.12%. This contributed to the annual value of $162.9 million for FY2024, which is 545.98% up from last year.
  • Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity amounted to $252.4 million in Q3 2025, which was up 16575.71% from $187.4 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity's 5-year high stood at $252.4 million during Q3 2025, with a 5-year trough of $70.3 million in Q2 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity averaged around $157.2 million, with its median value being $159.7 million (2023).
  • In the last 5 years, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity plummeted by 5598.55% in 2024 and then soared by 16648.7% in 2025.
  • Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity (Quarter) stood at $154.5 million in 2023, then increased by 5.46% to $162.9 million in 2024, then surged by 54.98% to $252.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $252.4 million for Q3 2025, versus $187.4 million for Q2 2025 and $192.9 million for Q1 2025.